Rare Disease Clinical Trials Research Report 2026: $21.34 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]
Nasdaq, Inc. (NDAQ)
Last nasdaq, inc. earnings: 4/22 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nasdaq.com
Company Research
Source: Yahoo! Finance
trials, leveraging AI for optimization, decentralized trial models, and personalized medicine focus. Growth is driven by enhanced collaboration, faster approvals, and client-centric innovations. Rare Disease Clinical Trials Market Rare Disease Clinical Trials Market · GlobeNewswire Inc. Dublin, April 24, 2026 (GLOBE NEWSWIRE) -- The "Rare Disease Clinical Trials Market Report 2026" has been added to ResearchAndMarkets.com's offering. The rare disease clinical trials market is experiencing robust growth. From $13.3 billion in 2025, it is projected to rise to $14.65 billion in 2026, at a CAGR of 10.1%. This growth is driven by the expansion of orphan drug development, regulatory incentives, specialized clinical research organizations, academia-industry collaborations, and better diagnostic identification of rare diseases. Looking ahead, the market is expected to continue its upward trajectory, reaching $21.34 billion by 2030, with a CAGR of 9.9%. Key growth factors include t
Show less
Read more
Impact Snapshot
Event Time:
NDAQ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NDAQ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NDAQ alerts
High impacting Nasdaq, Inc. news events
Weekly update
A roundup of the hottest topics
NDAQ
News
- Nasdaq (NDAQ) had its "buy (b)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- AI-Powered Clinical Trial Site Feasibility Research Report 2026: $4.38 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]Yahoo! Finance
- Ovzon AB (FRA:OVZ) Q1 2026 Earnings Call Highlights: Record Earnings and Strategic Growth [Yahoo! Finance]Yahoo! Finance
- Clinical Trial Supplies Research Report 2026: $4.33 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]Yahoo! Finance
- Nasdaq Inc (NDAQ) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic AI ... [Yahoo! Finance]Yahoo! Finance
NDAQ
Earnings
- 4/23/26 - Beat
NDAQ
Sec Filings
- 4/23/26 - Form 8-K
- 4/7/26 - Form 4
- 4/7/26 - Form 4
- NDAQ's page on the SEC website